These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 12911016)

  • 1. McClellan's FDA: boon to industry, consumers, or both? New FDA chief plans to speed drug approval and reduce costs.
    Ault A
    Lancet; 2003 Aug; 362(9381):379-80. PubMed ID: 12911016
    [No Abstract]   [Full Text] [Related]  

  • 2. The big gap at the FDA.
    Stipp D
    Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178
    [No Abstract]   [Full Text] [Related]  

  • 3. What ails the FDA?
    Okie S
    N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA not NIH can speed new drugs.
    Miller HI
    Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
    [No Abstract]   [Full Text] [Related]  

  • 5. Muddied messages about FDA.
    Miller HI
    Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
    [No Abstract]   [Full Text] [Related]  

  • 6. User fees and beyond--the FDA Safety and Innovation Act of 2012.
    Kramer DB; Kesselheim AS
    N Engl J Med; 2012 Oct; 367(14):1277-9. PubMed ID: 23034017
    [No Abstract]   [Full Text] [Related]  

  • 7. Who would approve new drugs if there were no FDA?
    Gatty B
    Hosp Formul; 1995 Jan; 30(1):58, 57. PubMed ID: 10139726
    [No Abstract]   [Full Text] [Related]  

  • 8. Paying for drug approvals--who's using whom?
    Avorn J
    N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA reform plan edges closer to realisation.
    Marx V
    Lancet; 2012 Jun; 379(9832):2135. PubMed ID: 22690392
    [No Abstract]   [Full Text] [Related]  

  • 10. What ails the FDA?
    Jenny-Avital ER
    N Engl J Med; 2005 Jun; 352(24):2554-5. PubMed ID: 15962407
    [No Abstract]   [Full Text] [Related]  

  • 11. Confronting the future of the FDA.
    Serafini MW
    Natl J (Wash); 1996 Dec; 28(50):2704-5. PubMed ID: 10163877
    [No Abstract]   [Full Text] [Related]  

  • 12. Today's FDA.
    Slater EE
    N Engl J Med; 2005 Jan; 352(3):293-7. PubMed ID: 15659733
    [No Abstract]   [Full Text] [Related]  

  • 13. Coming closer to FDA reform.
    Cimmons M
    Nat Med; 1997 Sep; 3(9):940. PubMed ID: 9288707
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA: Congress mixes harsh medicine.
    Lawler A; Stone R
    Science; 1995 Aug; 269(5227):1038, 1040-1. PubMed ID: 7652549
    [No Abstract]   [Full Text] [Related]  

  • 16. New drug law to speed scientific review.
    Nature; 1992 Oct; 359(6396):563. PubMed ID: 1406977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biogenerics standoff.
    Herrera S
    Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
    [No Abstract]   [Full Text] [Related]  

  • 18. Perspectives. Approval process a moving target in FDA reform hearings.
    Rhein R
    Faulkner Grays Med Health; 1996 Feb; 50(8):suppl 1-4. PubMed ID: 10154482
    [No Abstract]   [Full Text] [Related]  

  • 19. Trouble at the office.
    Allison M
    Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
    [No Abstract]   [Full Text] [Related]  

  • 20. An FDA Commissioner for the 21st Century.
    Chandra A; Sachs RE
    N Engl J Med; 2017 Apr; 376(15):e31. PubMed ID: 28402241
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.